SCHEMBL20927353

SCHEMBL20927353

C=C(NCc1cccnc1)Nc1ccc(Oc2ccnc3cc(OC)c(C(N)=O)cc23)cc1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 15/20 0.61
RET P07949 7/20 0.61
AURKB Q96GD4 6/20 0.61
PDGFRA P16234 4/20 0.61
PDGFRB P09619 3/20 0.61
KIT P10721 3/20 0.61
FGFR1 P11362 3/20 0.61
FLT1 P17948 3/20 0.61
FLT4 P35916 3/20 0.61
ABL1 P00519 3/20 0.61
RIPK2 O43353 2/20 0.61
STK10 O94804 2/20 0.61
BCR P11274 2/20 0.61
SLC6A3 Q01959 2/20 0.61
DDR1 Q08345 2/20 0.61
MAP4K2 Q12851 2/20 0.61
PTK6 Q13882 2/20 0.61
DDR2 Q16832 2/20 0.61
RIPK3 Q9Y572 2/20 0.61
ERN1 O75460 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20927260 0.93 KDR (0.64) KDRRETAURKBPDGFRAPDGFRB
SCHEMBL19956992 0.91 KDR (0.61) KDRRETAURKBPDGFRAPDGFRB
SCHEMBL20927259 0.91 KDR (0.64) KDRRETAURKBPDGFRAPDGFRB
SCHEMBL20927339 0.89 KDR (0.64) KDRRETAURKBPDGFRAPDGFRB
SCHEMBL20927280 0.88 KDR (0.62) KDRRETAURKBPDGFRAPDGFRB
SCHEMBL20927278 0.88 KDR (0.64) KDRRETAURKBPDGFRAPDGFRB
SCHEMBL20927264 0.87 KDR (0.69) KDRRETAURKBPDGFRAPDGFRB
SCHEMBL20927279 0.87 KDR (0.62) KDRRETAURKBPDGFRAPDGFRB
SCHEMBL20927377 0.87 KDR (0.62) KDRRETAURKBPDGFRAPDGFRB
SCHEMBL19956952 0.84 KDR (0.55) KDRRETAURKBPDGFRAPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same Guangdong Raynovent Biotech Co., Ltd. (CN) 2020-05-19 US disclosed
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Guangdong Raynovent Biotech Co., Ltd. (CN) 2019-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME ABL1, LCK, ERBB2 KDR 150/4885RET 19/4885AURKB 189/4885
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same ABL1, LCK, ERBB2 KDR 150/4885RET 19/4885AURKB 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.